What are the major modifiable and non-modifiable risk factors for chronic kidney disease (CKD) for a didactic presentation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

CKD Risk Factors for Didactic Presentation

For a comprehensive didactic presentation on CKD risk factors, organize content into non-modifiable and modifiable risk factors, with emphasis that modifiable factors—particularly hypertension, diabetes, and albuminuria—are the primary targets for preventing CKD progression and reducing cardiovascular mortality.

Non-Modifiable Risk Factors

These factors identify high-risk populations requiring intensified screening and monitoring:

  • Age: Older adults have substantially higher CKD prevalence and absolute mortality risk, though relative risk from modifiable factors is paradoxically higher in younger patients 1
  • Male sex: Men with CKD are 50% more likely than women to progress to end-stage kidney disease (ESKD) 2
  • Race/ethnicity: Certain ethnic minorities, particularly Black and Hispanic populations, face higher CKD risk and faster progression 2
  • Family history: Genetic predisposition to CKD, hypertension, or cardiovascular disease significantly increases risk 3, 4
  • Low socioeconomic/educational status: Independently associated with higher CKD risk 3

Modifiable Risk Factors

Primary Drivers of CKD Development and Progression

Hypertension is the most critical modifiable risk factor, accounting for 34% of incident ESKD cases in the U.S. and affecting 72-90% of dialysis patients 3, 5. Blood pressure control is essential at all CKD stages 6, 7.

Diabetes mellitus causes diabetic kidney disease in 20-40% of patients with diabetes and is the leading cause of ESKD in the U.S. 6, 7. In type 1 diabetes, CKD typically develops after 10 years; in type 2 diabetes, it may be present at diagnosis 7.

Albuminuria (≥30 mg/g creatinine) is both a marker of kidney damage and an independent risk factor for CKD progression, cardiovascular disease, and mortality at all eGFR levels 6, 8. The degree of albuminuria directly correlates with progression risk 7.

Additional Modifiable Cardiovascular-Metabolic Risk Factors

Among U.S. adults with hypertension, multiple risk factors commonly coexist: 49.5% have obesity, 63.2% have hypercholesterolemia, 27.2% have diabetes, and 15.8% have CKD 3.

  • Obesity/overweight: BMI ≥25 kg/m² (≥23 kg/m² for Asian ancestry) or abdominal obesity (waist circumference ≥88 cm women/≥102 cm men; ≥80/≥90 cm for Asian ancestry) 9
  • Dyslipidemia: Elevated LDL cholesterol, triglycerides ≥150 mg/dL, low HDL cholesterol 3, 2
  • Smoking: Current cigarette smoking and secondhand smoke exposure 3, 4
  • Physical inactivity: Sedentary lifestyle and low fitness levels 3, 10
  • Unhealthy diet: Particularly low plant-based food consumption and high ultraprocessed food intake 10

CKD-Specific Progression Risk Factors

Once CKD is established, these factors accelerate progression 6:

  • Hyperglycemia: Poor glycemic control in diabetic patients
  • Proteinuria: Higher levels predict faster progression 11
  • Anemia: Lower hemoglobin associated with faster progression 11
  • Metabolic acidosis: Common in advanced CKD stages
  • CKD-mineral and bone disorders: Abnormal calcium, phosphate, PTH levels 6
  • Acute kidney injury episodes: Each AKI event increases progressive CKD risk 6, 8

Risk Stratification Framework

Use the KDIGO CGA classification system (Cause, GFR category, Albuminuria category) to stratify patients into four risk levels 12, 10:

  • Low risk: eGFR ≥60 mL/min/1.73 m² with albuminuria <3 mg/mmol
  • Moderate risk: eGFR ≥60 with albuminuria 3-30 mg/mmol OR eGFR 45-59 with albuminuria <3 mg/mmol
  • High risk: eGFR ≥60 with albuminuria >30 mg/mmol OR eGFR 45-59 with albuminuria 3-30 mg/mmol OR eGFR 30-44 with albuminuria <3 mg/mmol
  • Very high risk: eGFR 30-44 with albuminuria ≥3 mg/mmol OR eGFR <30 at any albuminuria level

Clinical Implications for Screening

Screen patients with any of these high-risk conditions using both urine albumin-to-creatinine ratio and serum creatinine for eGFR calculation 4, 7:

  • Diabetes (71% have hypertension) 3
  • Hypertension
  • Cardiovascular disease (34.2% prevalence in general population) 3
  • Age ≥60 years (23.2% prevalence) 4
  • Family history of kidney disease
  • Obesity/metabolic syndrome

Common Pitfall to Avoid

Do not rely on serum creatinine alone—it is an unreliable marker of kidney dysfunction 13. Always calculate eGFR using validated equations (CKD-EPI preferred) and measure albuminuria, as reduced eGFR without albuminuria is increasingly common in both type 1 and type 2 diabetes 7, 8.

Key Teaching Points

The relationship between risk factors is complex and interdependent—they share common pathophysiologic mechanisms including renin-angiotensin-aldosterone system activation, sympathetic nervous system overactivity, endothelial dysfunction, and chronic inflammation 3, 5. Early identification through systematic screening of at-risk populations, combined with aggressive modification of treatable risk factors (especially blood pressure, glycemic control, and albuminuria reduction), can prevent or delay CKD progression and reduce the exceptionally high cardiovascular mortality in this population 4, 2, 13.

References

Research

Identification of patients and risk factors in chronic kidney disease--evaluating risk factors and therapeutic strategies.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2001

Related Questions

In patients with chronic kidney disease who have hypertension or albuminuria, how should ACE inhibitors be initiated, dosed, monitored, and what are the contraindications and alternatives?
Which antidiabetic agents are safe and recommended for patients with chronic kidney disease?
What is the appropriate antihypertensive management for a 56-year-old male with uncontrolled hypertension (158/79 mm Hg), asymptomatic, currently on amlodipine 10 mg daily, chronic kidney disease with eGFR 13 mL/min/1.73 m², and diabetes with hemoglobin A1c 7.2%?
In a 60-year-old patient with chronic kidney disease, hypertension, type 2 diabetes, currently taking metformin, an angiotensin-converting enzyme inhibitor, and a statin, and with an atherosclerotic cardiovascular disease risk of 18%, what is the next recommended therapy?
What is the safest first‑line muscle relaxant for an adult with chronic kidney disease?
What is the clinical significance and recommended management for an isolated elevated anti‑thyroglobulin (anti‑Tg) with normal anti‑thyroid peroxidase (anti‑TPO) antibodies?
In a patient with chronic lymphocytic leukemia (CLL) who has a new diagnosis of hepatitis E virus (HEV) infection, how should management be proceeded?
What is the appropriate treatment for non-specific mesenteric lymphadenitis in an 11-year-old girl presenting with abdominal pain?
What are the recommended octreotide (somatostatin analog) dosing regimens and routes for acute variceal bleeding, secondary prophylaxis of variceal hemorrhage, carcinoid syndrome, acromegaly, refractory hypoglycemia, and congenital hyperinsulinism?
Can vasopressin and norepinephrine (Levophed) be administered through the same intravenous line?
What are the name, strength, dosing schedule, indication, and safety considerations for the medication my doctor prescribed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.